HealthTech

Digital health in Pakistan is built on top of a regulatory system designed for hospitals, pharmacies, and paper files. The statutes are real and enforced — the Drugs Act 1976, the DRAP Act 2012, provincial healthcare commission laws, professional regulation through the PM&DC — but none of them was written with a consultation app, a home phlebotomy service, or a diagnostic algorithm in mind. The result is a sector where the central legal skill is honest characterization: deciding what each product is under laws that predate it, saying clearly which questions have settled answers and which do not, and building the operating model so the company is defensible under the reading a regulator is most likely to adopt.

What the product is, legally

Every healthtech engagement starts with classification, because everything else follows from it. Software that diagnoses or directs treatment raises the medical-device question under the Medical Devices Rules 2017; the definition is capable of reaching software, though its application to standalone digital products remains thinly developed in Pakistan [TO BE VERIFIED BY REVIEWING LAWYER]. A platform that organizes care raises the healthcare-establishment question under the provincial commission statutes — the Punjab Healthcare Commission Act 2010 for a Lahore-based operator, with parallel regimes in Sindh, KP, and Islamabad. A pharmacy marketplace raises the drug sale licensing question under the Drugs Act 1976, administered provincially and silent on the internet. In each case the classification is driven less by the technology than by claims and conduct: what the marketing says the product does, and who actually exercises clinical judgment. We scrutinize the intended-use language as hard as the architecture, because regulators will. Health advertising carries its own rules — therapeutic claims for products sit within DRAP's remit, and exaggerated outcome claims by platforms invite both regulatory attention and complaint jurisdiction — so the review covers the campaign, not just the product.

The gray areas, stated honestly

Some of what healthtech clients most want settled is not settled, and we think the credible position is to say so. Telemedicine has no dedicated Pakistani framework as of mid-2026: no telehealth licence, no statutory standards for remote consultation, no explicit rules on e-prescribing. That does not make it unlawful — registered practitioners consulting remotely operate within the general law of medical practice — but it means the guardrails are the platform's to build: verified PM&DC registration for every practitioner, documented consent that explains the limits of remote care, consultation records kept to the standard a commission inquiry would expect, escalation pathways for cases that need physical examination, and restraint on remote prescribing of higher-risk categories. Platforms that build these guardrails hold two advantages. They are defensible under current law, and they are positioned for the framework Pakistan will eventually adopt, which is unlikely to demand less. Cross-border models add a further unsettled layer — a Pakistani patient consulting a foreign-registered doctor, or a Pakistani platform serving diaspora patients abroad, raises registration and jurisdiction questions no Pakistani instrument currently answers, and we structure those models around the strictest plausible reading rather than the most convenient one.

Patient data as an existential asset

A healthtech company's data practices deserve more care than the statute book currently compels. Pakistan's general data-protection legislation remains pending as of mid-2026, so the binding obligations around patient data come from an assembly of sources: the confidentiality that practitioners owe as a matter of professional ethics and that platforms inherit through them, the contracts with patients, hospitals, labs, and insurers, and the offences in PECA 2016 around unauthorized access to and disclosure of data. We convert that assembly into a single written standard for each client — lawful basis and consent flows, role-based access, retention and deletion rules, vendor terms for every processor touching health records, and a breach-response plan with names in it. The commercial logic is blunt: health platforms run on trust, a breach is the fastest way to destroy it, and the company's conduct in the first week after an incident will be judged against the standard it wrote for itself.

How we serve healthtech companies

We act for telehealth platforms, diagnostics and lab-tech companies, pharmacy and e-commerce health models, and hospital-facing software vendors — on classification and regulatory strategy, commission and DRAP interactions, the practitioner and partner agreements that carry the clinical risk, and the data standard underneath all of it. Where the law is unsettled we give clients the honest map: the defensible route, the aggressive route, and the difference in exposure between them. The regulatory position described here is stated as of mid-2026 — DRAP rulemaking, provincial commission practice, and the pending data legislation are all capable of moving — and each engagement begins by confirming the instruments then in force.